Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nivolumab and metformin work in treating patients with
microsatellite stable (MSS) stage IV colorectal cancer that has not responded to previous
treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's
immune system attack the cancer, and may interfere with the ability of tumor cells to grow
and spread. Metformin is an antidiabetic drug that and may reduce the risk of colorectal
cancer development in patients. Giving nivolumab and metformin may work better in treating
patients with refractory microsatellite metastatic colorectal cancer.